IGC Pharma, Inc. (IGC)
0.1974
+0.01
(+5.06%)
USD |
NYAM |
Nov 18, 16:00
0.1974
0.00 (0.00%)
After-Hours: 20:00
IGC Pharma Enterprise Value : 21.94M for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | 21.94M |
| November 16, 2026 | 20.47M |
| November 13, 2026 | 20.58M |
| November 12, 2026 | 21.55M |
| November 11, 2026 | 23.20M |
| November 10, 2026 | 22.87M |
| November 09, 2026 | 23.83M |
| November 06, 2026 | 23.33M |
| November 05, 2026 | 22.07M |
| November 04, 2026 | 22.75M |
| November 03, 2026 | 21.73M |
| November 02, 2026 | 22.51M |
| October 30, 2026 | 21.61M |
| October 29, 2026 | 23.23M |
| October 28, 2026 | 27.75M |
| October 27, 2026 | 28.80M |
| October 26, 2026 | 29.03M |
| October 23, 2026 | 28.59M |
| October 22, 2026 | 28.78M |
| October 21, 2026 | 28.19M |
| October 20, 2026 | 28.47M |
| October 19, 2026 | 28.13M |
| October 16, 2026 | 28.59M |
| October 15, 2026 | 29.51M |
| October 14, 2026 | 29.26M |
| Date | Value |
|---|---|
| October 13, 2026 | 30.76M |
| October 12, 2026 | 32.02M |
| October 09, 2026 | 32.46M |
| October 08, 2026 | 33.03M |
| October 07, 2026 | 32.47M |
| October 06, 2026 | 32.47M |
| October 05, 2026 | 32.70M |
| October 02, 2026 | 31.89M |
| October 01, 2026 | 31.33M |
| September 30, 2026 | 31.20M |
| September 29, 2026 | 28.12M |
| September 28, 2026 | 28.79M |
| September 25, 2026 | 29.65M |
| September 24, 2026 | 29.52M |
| September 23, 2026 | 30.03M |
| September 22, 2026 | 29.71M |
| September 21, 2026 | 28.79M |
| September 18, 2026 | 29.92M |
| September 17, 2026 | 28.01M |
| September 16, 2026 | 28.59M |
| September 15, 2026 | 28.06M |
| September 14, 2026 | 28.94M |
| September 11, 2026 | 29.26M |
| September 10, 2026 | 29.71M |
| September 09, 2026 | 29.56M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 15.77M |
| CNBX Pharmaceuticals, Inc. | 1.305M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | -104.09M |
| Fulcrum Therapeutics, Inc. | -14.38M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.046M |
| Revenue (Quarterly) | 0.328M |
| Total Expenses (Quarterly) | 2.374M |
| EPS Diluted (Quarterly) | -0.0187 |
| Gross Profit Margin (Quarterly) | 6.10% |
| Profit Margin (Quarterly) | -623.8% |
| Earnings Yield | -40.63% |
| Normalized Earnings Yield | -40.58 |